Latest news with #StephenThorne
BBC News
3 days ago
- Entertainment
- BBC News
BBC Archive: Doctor Who: The Legend of Omega
As season two of Doctor Who draws to a close and the Doctor once again faces not just the Rani, but Omega too, BBC Archives takes a look back at the creation of the character of Omega and his previous encounters with the Doctor. "Omega? But that's impossible. Omega was destroyed." The Doctor (1973) Omega first appeared in the 1973 story The Three Doctors – the first multi-Doctor story in the Whoniverse. The character took a while to develop, as can be seen in these letters from Doctor Who script editor Terrence Dicks to story writers Bob Baker and Dave Martin. This first letter shows that the character of Omega (at this stage named 'Ohm') and the setting of the anti-matter universe he lives in were established early on in the story writing process. As plans for the story progressed, Terrence Dicks continued to correspond with writers Bob Baker and Dave Martin. He suggests that they could create three different aspects of Ohm "to match the three Doctors ", although "the most evil Ohm would finally gain the upper hand". By the time The Three Doctors was seen on screen Ohm had become Omega, the powerful temporal engineer of Time Lord mythology. No wonder the Rani would seek him out for her plans. "Without me, there would be no time travel" Omega (1973) The imposing figure of Omega was originally played by statuesque actor Stephen Thorne. Stephen had previously appeared in the Doctor Who story The Dæmons as the equally towering Azal. He was an actor known for his great voice as well as his height, and could be often heard on BBC radio in addition to his appearances on television. The character of Omega returned to Doctor Who in the 1983 story Arc of Infinity, now played by Ian Collier, where he still hoped to escape the anti-matter universe. In Arc of Infinity Omega tried to use Time Lord technology to give himself a new physical form, copying that of the Doctor, and so was briefly also played by Peter Davison. "Things could have been different. Power, and the greatness of Omega, could have been yours." Omega (1983) Omega returned to Doctor Who in The Reality War having become the god the Time Lord legends created. This time there was no mask wearing actor inside a suit, but the whole character was created by CGI. But the Doctor was still able to force him to remain trapped in the Underverse, maybe to meet again some day, because legends never really die.
Associated Press
25-03-2025
- Business
- Associated Press
KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL. The presentation will focus on the company's clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, advanced solid tumors. VET3-TGI is a novel oncolytic immunotherapy which is designed to systemically target and selectively kill tumor cells while also expressing an immuno-stimulatory transgene payload consisting of interleukin-12 and a TGFbeta inhibitor. Details on the poster presentation are below: Presentation Title: Mechanisms of synergy between TGF-beta inhibitor and IL12 expression from the systemically deliverable clinical oncolytic immunotherapy VET3-TGI Abstract Number: 484 Session Date & Time: Sunday, April 27, 2025; 2-5 pm Presenter: Stephen Thorne, PhD, Co-founder and Chief Scientific Officer, KaliVir Immunotherapeutics About KaliVir Immunotherapeutics, Inc. KaliVir Immunotherapeutics is a clinical-stage biotechnology company at the forefront of developing next-generation oncolytic immunotherapies. By harnessing the unique advantages of the vaccinia platform, KaliVir engineers optimized viral backbones to create innovative candidates for cancer treatment. The Company's proprietary Vaccinia Enhanced Template (VET ™ ) platform integrates multiple genetic modifications, allowing for the systemic delivery of oncolytic vaccinia candidates and the targeted expression of therapeutic transgenes within tumors. The Company is actively expanding its pipeline using the VET ™ platform, with its capabilities validated through strategic global partnerships with Astellas Pharma and Roche. Currently, the Company has two product candidates in Phase 1 clinical trials: ASP1012, exclusively licensed and led by Astellas Pharma, and its internal lead candidate, VET3-TGI. With multiple therapeutic candidates progressing through clinical development, KaliVir is positioned as a leader in innovative cancer therapies. Headquartered in Pittsburgh, Pennsylvania, KaliVir is committed to revolutionizing cancer treatment. For more information, visit Lauren Arnold SOURCE: KaliVir Immunotherapeutics, Inc. Copyright Business Wire 2025. PUB: 03/25/2025 04:45 PM/DISC: 03/25/2025 04:45 PM
